Top

Cancer Causes & Control

Published in:

01-08-2012 | Original paper

Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case–control study

Authors: Johan Brändstedt, Martin Almquist, Jonas Manjer, Johan Malm

Published in: Cancer Causes & Control | Issue 8/2012

Abstract

Objective

To examine the risk of prostate cancer in relation to pre-diagnostic serum levels of vitamin D (25OHD₂ and 25OHD₃), PTH, and calcium.

Methods

Nine hundred forty-three incident prostate cancer cases were identified in the Malmö Diet and Cancer Study cohort, and each was matched with one control using incidence density matching with age as the underlying timescale. We also matched for calendar time and age at inclusion. Logistic regression analysis yielded odds ratios with 95 % confidence intervals for different quartiles and deciles. All analyses were repeated stratified for age and body mass index (BMI).

Results

We found a weak trend toward increasing prostate cancer risk with rising vitamin D levels (p-trend across quartiles, 0.048). Dividing the cohort into deciles showed a nonlinear association. Compared to decile one, the prostate cancer risk was highest in deciles seven and eight, which corresponded to vitamin D levels of 91–97 nmol/L (1.68; 1.06–2.68), and 98–106 nmol/L (1.80; 1.13–2.85). In the other deciles, there was no association between prostate cancer risk and vitamin D levels. Albumin-adjusted calcium was positively associated with an increased risk for prostate cancer among men aged 55–65 with a BMI <25 (2.07; 1.08–3.97). No association was observed between pre-diagnostic PTH and subsequent prostate cancer incidence, and the stratified analyses revealed no other convincing relationships.

Conclusions

This study suggests a possible weak positive nonlinear association between vitamin D and the risk of prostate cancer.

Gronberg H (2003) Prostate cancer epidemiology. Lancet 361(9360):859–864PubMedCrossRef

Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10(5A):1307–1311PubMed

Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, Feldman D (2007) Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J Bone Miner Res 22(Suppl 2):V74–V80PubMedCrossRef

Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP (1997) 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6(9):727–732PubMed

Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P (2000) Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11(9):847–852PubMedCrossRef

Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G et al (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108(1):104–108PubMedCrossRef

Albanes D, Weinstein SJ, Mondul AM, Virtamo J (2011) Circulating Vitamin D and risk of prostate cancer—response. Cancer Epidemiol Biomarkers Prev. Epub 2011/11/03

Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT et al (1993) Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2(5):467–472PubMed

Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ (1996) Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5(2):121–126PubMed

10.

Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR (2004) Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 89–90(1–5):533–537PubMedCrossRef

11.

Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D et al (2007) A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4(3):e103PubMedCrossRef

12.

Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A et al (1998) Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9(4):425–432PubMedCrossRef

13.

Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E (2004) Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15(3):255–265PubMedCrossRef

14.

Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 128(6):1414–1424

15.

Yin L, Raum E, Haug U, Arndt V, Brenner H (2009) Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol 33(6):435–445PubMedCrossRef

16.

Ritchie CK, Thomas KG, Andrews LR, Tindall DJ, Fitzpatrick LA (1997) Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 30(3):183–187PubMedCrossRef

17.

Liao J, Schneider A, Datta NS, McCauley LK (2006) Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res 66(18):9065–9073PubMedCrossRef

18.

Fedirko V, Riboli E, Bueno-de-Mesquita HB, Rinaldi S, Pischon T, Norat T, et al. Pre-diagnostic circulating parathyroid hormone concentration and colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Cancer Epidemiol Biomarkers Prev

19.

Schwartz GG (2008) Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev 17(3):478–483. Epub 2008/03/20

20.

Murray RM, Grill V, Crinis N, Ho PW, Davison J, Pitt P (2001) Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 86(9):4133–4138. Epub 2001/09/11

21.

Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA et al (1998) Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58(3):442–447PubMed

22.

Skinner HG, Schwartz GG (2009) A prospective study of total and ionized serum calcium and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 18(2):575–578PubMedCrossRef

23.

Skinner HG, Schwartz GG (2008) Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 17(9):2302–2305. Epub 2008/09/05

24.

Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC (2007) Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 121(7):1571–1578PubMedCrossRef

25.

Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T et al (2007) Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109(4):675–684PubMedCrossRef

26.

Halthur C, Johansson AL, Almquist M, Malm J, Gronberg H, Manjer J et al (2009) Serum calcium and the risk of prostate cancer. Cancer Causes Control 20(7):1205–1214PubMedCrossRef

27.

Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M et al (2001) The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 10(6):489–499PubMedCrossRef

28.

Wallstrom P (2002) Diet, lifestyle, antioxidants and biomarkers of cancer risk. An epidemiological report from the Malmö Diet and cancer cohort. Thesis, Lund University, Malmö

29.

Anker P, Wieland E, Ammann D, Dohner RE, Asper R, Simon W (1981) Neutral carrier based ion-selective electrode for the determination of total calcium in blood serum. Anal Chem 53(13):1970–1974PubMedCrossRef

30.

Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP et al (2007) The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 85(3):649–650PubMed

31.

Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N et al (2008) Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100(11):796–804PubMedCrossRef

32.

Dusso AS, Brown AJ, Slatopolsky E (2005) Vitamin D. Am J Physiol Renal Physiol 289(1):F8–F28PubMedCrossRef

33.

Pero RW, Olsson A, Bryngelsson C, Carlsson S, Janzon L, Berglund G et al (1998) Quality control program for storage of biologically banked blood specimens in the Malmo Diet and Cancer Study. Cancer Epidemiol Biomarkers Prev 7(9):803–808PubMed

34.

Hollis BW (2008) Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am J Clin Nutr 88(2):507S–510SPubMed

35.

Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV et al (1999) Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 59(7):491–500PubMedCrossRef

36.

Gallagher SK, Johnson LK, Milne DB (1989) Short-term and long-term variability of indices related to nutritional status. I: Ca, Cu, Fe, Mg, and Zn. Clin Chem 35(3):369–373PubMed

37.

Ankrah-Tetteh T, Wijeratne S, Swaminathan R (2008) Intraindividual variation in serum thyroid hormones, parathyroid hormone and insulin-like growth factor-1. Ann Clin Biochem 45(Pt 2):167–169PubMedCrossRef

38.

Viljoen A, Singh DK, Twomey PJ, Farrington K (2008) Analytical quality goals for parathyroid hormone based on biological variation. Clin Chem Lab Med 46(10):1438–1442PubMedCrossRef

39.

Nilsson-Ehle P (2003) Laurells klinisk kemi i praktisk medicin: Studentlitteratur AB

40.

Leifsson BG, Ahren B (1996) Serum calcium and survival in a large health screening program. J Clin Endocrinol Metab 81(6):2149–2153. Epub 1996/06/01

41.

Kukreja SC, Shanmugam A, Lad TE (1988) Hypocalcemia in patients with prostate cancer. Calcif Tissue Int 43(6):340–345. Epub 1988/12/01

42.

Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48(1):27–33PubMedCrossRef

43.

Peterlik M, Boonen S, Cross HS, Lamberg-Allardt C (2009) Vitamin D and calcium insufficiency-related chronic diseases: an emerging world-wide public health problem. Int J Environ Res Public Health 6(10):2585–2607PubMedCrossRef

44.

Hoffman RM, Stone SN, Espey D, Potosky AL (2005) Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer 5:27PubMedCrossRef

45.

Lund Oci (2006) Kvalitetsregister för prostatacancer, Regional rapport för diagnosår 2006, Södra sjukvårdsregionen

46.

Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, et al (2011) Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PloS one 6(4):e18625. Epub 2011/04/16

Title: Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case–control study
Authors: Johan Brändstedt
Martin Almquist
Jonas Manjer
Johan Malm
Publication date: 01-08-2012
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 8/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-012-9948-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2012

Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort

Hematologic malignancies: an opportunity to fill a gap in cancer surveillance

Height and pancreatic cancer risk: a systematic review and meta-analysis of cohort studies

Liquid-based cervical cytology using ThinPrep technology: weighing the pros and cons in a cost-effectiveness analysis

Comparison of breast and cervical cancer screening utilization among rural and urban Hispanic and American Indian women in the Southwestern United States

Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer